Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...

DelveInsight's Metastatic Non-Small Cell Lung Cancer Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, February 5, 2025 ...

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Among heavily pretreated patients with KRAS G12C-mutant unresectable or metastatic colorectal cancer (mCRC), the combination of Krazati (adagrasib) and Erbitux (cetuximab) has shown clinically ...

Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have ...

Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Gynecological Cancer. According to GlobalData, Phase I drugs for Gynecological Cancer have a 74% phase ...

In a phase 2 trial (CTRI/2023/07/055785), ado-trastuzumab emtansine (T-DM1; Kadcyla) was well-tolerated in HER2-positive biliary tract adenocarcinoma, but it did not show a statistically significant ...

After hours: February 7 at 5:02:52 p.m. EST ...